STOCK TITAN
  1. Home
  2. MYPHY

Mayne Pharma (MYPHY) Stock Price, News & Analysis

MYPHY OTC

Company Description

Mayne Pharma (OTC: MYPHY) is classified in the medicinal and botanical manufacturing industry within the Manufacturing sector.

This page collects what Stock Titan holds for MYPHY, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

earnings
—

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

acquisition
—

Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

acquisition
—

NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent

—

MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL

—

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

fda approval

Mayne Pharma has 7 recent news articles. Key topics include earnings, acquisition, fda approval. View all MYPHY news →

SEC Filings

View All

No SEC filings available for MYPHY.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

MYPHY Company Profile & Sector Positioning

Mayne Pharma (MYPHY) operates in the Medicinal and Botanical Manufacturing industry within the broader Manufacturing sector and is listed on the OTC.